IDH2 and leukemia: To evaluate the potential role of wild-type (wt) IDH2 in AML disease development, we first analyzed the expression of IDH2 in primary AML samples in comparison with normal cells, using the leukemia datasets from Oncomine [25] and BloodSpot [26], which contained RNA sequencing (RNA-seq) data from clinical specimens of AML patients.